Thermal spa treatment to improve symptoms of primary ciliary dyskinesia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with confirmed primary ciliary dyskinesia are randomized to either start with a 3-week balneotherapy (thermal spa) course followed by 6 months of follow-up, or to receive standard care for 6 months and then the spa treatment with further follow-up. The trial collects ENT and lung function measures, quality-of-life questionnaires, hearing tests, and nasal swabs, and tracks infection frequency and antibiotic use. Primary comparisons focus on ENT symptom change and daily quality of life, with secondary outcomes including hearing and pulmonary function. The design allows within- and between-group comparisons over a 12-month period due to the sequential crossover for the delayed group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of Primary Ciliary Dyskinesia (PCD) based on electron microscopy analysis of ciliary ultrastructure and/or genetic testing (i.e., two unambiguous mutations in genes known to be involved in PCD, particularly in cases with normal ciliary ultrastructure \[\~20% of patients\], atypical ultrastructural findings, or suggestive symptoms in a family with a known causal gene).
* Age over 18 years.
* Stable maintenance treatment for at least 1 month prior to inclusion.
* Performance Status (PS) ≤ 1.
* Patient has received the study information sheet and signed the informed consent form.
* Patient has valid health insurance coverage.

Exclusion Criteria:

* Participation in a thermal spa treatment within the past year.
* Severe general health deterioration or debilitating conditions.
* Severe or recent heart failure.
* Labile hypertension.
* Venous insufficiency or deep vein thrombosis within the past 3 months.
* Recent unhealed fracture.
* Unhealed skin lesions (wounds, pressure sores, eczema).
* Contagious or progressive diseases.
* Recent cancer (less than 5 years).
* Ongoing or recent (within the past month) pulmonary or ENT exacerbation at inclusion.
* Ongoing treatment with immunomodulatory or immunosuppressive drugs (due to the risk of potentially severe opportunistic infections).
* Ongoing or recent (within the past month) extra-respiratory or ENT infectious flare-up.
* Positive pre-cure bacteriological testing for multidrug-resistant Pseudomonas aeruginosa, MRSA, Mycobacterium abscessus, or other multidrug-resistant pathogenic bacteria.
* Fever \> 38.5°C.
* Recently worsened dyspnea (\< 1 month).
* History of serious adverse effects or intolerance during a previous thermal spa treatment.
* Participation in another clinical trial with an exclusion period.
* Considered a vulnerable person, as defined by Articles L1121-5 to L1121-8 of the French Public Health Code:

Pregnant women, women in labor, and breastfeeding mothers.

Individuals deprived of liberty by judicial or administrative decision, or those hospitalized without consent under Articles L.3212-1 and L.3213-1 (excluding Article L.1121-8), and persons admitted to a healthcare or social institution for reasons other than research.

Adults under legal protection or unable to give informed consent.

Where it's running

• Institut Universitaire de la Face et du Cou
  Nice, France Recruiting

Study contacts

• Study coordinator: Colin DEBAIGT
• Email: colin.debaigt@nice.unicancer.fr
• Phone: +33492031661

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bronchial hyperresponsiveness in children with primary ciliary dyskinesia

  This will see if children with primary ciliary dyskinesia have sensitive airways (bronchial hyperresponsiveness) by using a methacholine breathing challenge and related tests.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07288827

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Glycine and magnesium plus thiamine for primary ciliary dyskinesia

  This trial will test whether daily oral glycine and magnesium with thiamine, alone or combined, can help people aged 5 and older with primary ciliary dyskinesia clear mucus and breathe better.

  Recruiting Instituto Nacional de Enfermedades Respiratorias · Mexico City · NCT06959251

• Observational study on Primary Ciliary Dyskinesia

  This study looks at people with Primary Ciliary Dyskinesia to see what factors might affect how severe their condition is and to help improve their care.

  Recruiting at 18 sites Institut National de la Santé Et de la Recherche Médicale, France · Besançon and 31 other locations · NCT05951478

• Using nasal nitric oxide testing to improve diagnosis of primary ciliary dyskinesia

  This study is testing if a simple nasal test can help doctors diagnose primary ciliary dyskinesia in people aged 2 and older who show symptoms of the condition.

  Recruiting Connecticut Children's Medical Center · Hartford, Connecticut · NCT05889013

• Nasal nitric oxide testing for better care in primary ciliary dyskinesia

  This study is trying to see if measuring nitric oxide in the nose can help doctors diagnose primary ciliary dyskinesia more accurately for patients at Arkansas Children's Hospital.

  Recruiting Arkansas Children's Hospital Research Institute · Little Rock, Arkansas · NCT05287022

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.